Discontinued — last reported Q3 '25
Amgen Business Segments — Income (Loss) from Equity Method Investments increased by 155.6% to $10.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 135.7%, from -$28.00M to $10.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Positive income indicates successful strategic partnerships, while losses may suggest underperformance of joint ventures.
Reflects the company's share of profits or losses from entities in which it holds a significant influence but not full c...
Standard for companies with significant joint ventures or minority stakes in other biotech firms.
amgn_segment_reportable_segment_income_loss_from_equity_method_investments| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|
| Value | $27.00M | $12.00M | -$28.00M | -$11.00M | -$18.00M | $10.00M |
| QoQ Change | — | -55.6% | -333.3% | +60.7% | -63.6% | +155.6% |
| YoY Change | — | — | — | -140.7% | -250.0% | +135.7% |